Used as main image by Phynd in search results and profile page

Patrick Alan Hagen, MD

Medical Oncology, Hematology, Hematology & Oncology, Internal Medicine

Provider Groups

  • Loyola Medicine Physician

  • Loyola Physician Partners

Primary Contact

(888)584-7888
Appointments (New Patients Welcome)
Provider Groups
  • Loyola Medicine Physician

  • Loyola Physician Partners

Primary Contact
(888)584-7888

Services & Specialties

Areas of Specialization

  • Hematology
  • Hematology & Oncology
  • Internal Medicine
  • Medical Oncology

Clinical Interests

Conditions Treated

  • cancer chemotherapy
  • bone marrow aspiration
  • stem cell harvest
  • cellular therapy
  • cellular therapy - allogeneic
  • cellular therapy - autologous
  • cellular therapy - chimeric antigen T-cell (CAR-T)
  • bone marrow biopsy

Locations & Contact

Primary Location

Loyola University Medical Center

2160 S First Ave
Maywood , IL 60153

Loyola University Medical Center

Loyola Cancer Care & Research at the Marjorie G. Weinberg Cancer Center at Melrose Park

715 W N Ave
Melrose Park , IL 60160

View hours
Monday
12:00am - 12:00am
Tuesday
12:00am - 12:00am
Wednesday
12:00am - 12:00am
Thursday
12:00am - 12:00am
Friday
12:00am - 12:00am
Sunday
12:00am - 12:00am
Loyola Cancer Care & Research at the Marjorie G. Weinberg Cancer Center at Melrose Park

About

My work at Loyola University incorporates both pre-clinical and clinical research as well as direct patient care. I am passionate about working with patients to find the best treatment choice tailored to each individual. My focus is primarily on plasma cell disorders including monoclonal gammopathy of unknown significance (MGUS), smoldering myeloma, multiple myeloma, plasma cell leukemia, amyloidosis (both systemic and ATTR), light chain deposition disease, and POEMS disease. However, I see patients for all malignant hematology conditions including acute and chronic leukemia, non-hodgkin and hodgkins lymphoma, a well as MDS and aplastic anemia. In particular, I focus on the role of high dose chemotherapy and autologous or allogeneic transplant as well as cellular therapy (CAR-T) in the care of patients. Further, it is my goal that every patient be offered and ideally treated on a clinical trial in order to improve patient outcomes. I am involved in translational as well as early and late phase clinical trial development.

Finally, I truly enjoy working with referring physicians and am passionate about finding the best treatment for mutual patients either here at Loyola or ideally locally if possible. I am always available to discuss the best care options for patients regardless of intent to refer to us for a second opinion or clinical trial opportunities.

Academic Title

Associate Professor

Leadership Title

Associate Director of the Cardinal Bernardin Cancer Center Clinical Trials Office
Interim Director of the Transplantation and Cellular Therapy Program

Additional Resources

Education & Certifications

Education

Education:
St George's University School of Medicine (2011)

Residency:
University of Minnesota Medical School (2014)

Fellowship:
Loyola University Stritch School of Medicine (2017)

Board Certifications

Hematology, Hematology, American Board of Internal Medicine Subspecialty (2020)

Medical Oncology, Medical Oncology, American Board of Internal Medicine Subspecialty (2017)

Internal Medicine, Internal Medicine, American Board of (2014)

Provider Groups

Loyola Medicine Physician

Loyola Physician Partners

Provider Ratings

The following ratings and reviews are based on verified feedback collected from independently administered patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions. Patient identities are withheld to ensure confidentiality and privacy. Learn More >

4.9 out of 5

(160 ratings)

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

40 Reviews

06/26/2024

always very good

06/25/2024

From the first time I ever received medical care from Loyola, I could not be more pleased with the professionalism, attention and comfort from each and every one of your medical teams.

06/25/2024

Dr. Hagen explains my treatment plan clearly and thoroughly.

06/19/2024

I am very happy with the care I receive from Dr hagen.

06/18/2024

Muy buena

06/10/2024

Fantastic experience in every respect.

06/10/2024

Very good person

05/20/2024

Knowledge, kind, caring,

05/06/2024

All was well

04/25/2024

This was my first time meeting Dr. Hagan. He is such a warm, inviting, calm spirited, and knowledgeable physician. He listened to my concerns without judgement. He answered all of my questions and presented me with helpful suggestions that I took to heart. His overall opinion of my current treatment was absolutely what I wanted to hear. He calmed a lot of fears and for that I was truly grateful. I will not hesitate to make another appointment to see Dr. Hagan in the future .again

04/18/2024

I’m very happy with dr Hagen he listen and. Has patience

04/01/2024

Muy bueno

04/01/2024

They're very good

03/04/2024

Dr. Hagen always gives me the time to go over everything

02/07/2024

Professional, thorough, caring

02/06/2024

I am a physician. Patrick Hagen has treated me for almost 2 years in a manner that I would like to think that I treat patients.

01/23/2024

Felt very comfortable and calm

01/16/2024

He changes treatment visit to visit.

12/18/2023

Dr. Hagan was professional, gave good explanations and was courteous and friendly.

12/04/2023

Explained my current condition in great detail.

11/28/2023

I trust the provider explecitly

11/22/2023

I felt very comfortable talking to this provider.

11/21/2023

Initial visit was encouraging We agreed on treatment plan that had the best chance of a successful outcome

11/15/2023

The best i have ever been treated no lie

11/09/2023

Patient and caring

11/09/2023

organized a well-run treatment plan

11/04/2023

All staff members helpful and courteous

10/25/2023

Just keep up the work that you’re doing much appreciated

10/21/2023

Very knowledgeable answers to my questions

09/27/2023

Dr. Hagen is very knowledgeable in all aspects of my cancer

09/24/2023

Dr. Hagen was great. This was my first appointment with him. He understood my case history.

09/08/2023

The provider listened to all my concern and explained my options based on the information available at the time.

09/05/2023

Dr Hagan and Loyola in general are providing me with the best possible care

08/23/2023

Very caring and explained the results and follow up in a way I was able to understand it !

08/10/2023

Very good overall experience. Dr very knowledgeable and explains everything thoroughly. Listed intently to my questions.

07/27/2023

They have worked to give me a longer life and I am grateful for that.

07/24/2023

A pleasant and trustworthy physician

07/06/2023

Very honest and helpful.

07/06/2023

They are all nice

07/05/2023

Still the same good people
Show more

Publications

  • Autologous stem cell transplantation in AL amyloidosis: Muddy waters. Hagen, P.; D'Souza, A.; Blood reviews
  • Caspase 8 deletion causes infection/inflammation-induced bone marrow failure and MDS-like disease in mice. Liu, S.; Joshi, K.; Zhang, L.; Li, W.; Mack, R.; Runde, A.; Hagen, P. A.; Barton, K.; Breslin, P.; Ji, H. L.; Kini, A. R.; Wang, Z.; Zhang, J.; Cell death & disease
  • Busulfan, melphalan and carfilzomib high-dose chemotherapy and autologous haematopoietic stem cell transplantation in multiple myeloma. Hagen, P.; Norton, J.; Tsai, S.; Campo, L.; Lee, M.; Gomez, K.; Stiff, P.; British journal of haematology
  • Distinct roles of hematopoietic cytokines in the regulation of leukemia stem cells in murine MLL-AF9 leukemia. Li, Y.; Seet, C. S.; Mack, R.; Joshi, K.; Runde, A. P.; Hagen, P. A.; Barton, K.; Breslin, P.; Kini, A.; Ji, H. L.; Zhang, J.; Stem cell reports
  • Multicenter analysis of immunosuppressive medications on the risk of malignancy following adult solid organ transplantation. Shaw, R.; Haque, A. R.; Luu, T.; O'Connor, T. E.; Hamidi, A.; Fitzsimons, J.; Varda, B.; Kwon, D.; Whitcomb, C.; Gregorowicz, A.; Roloff, G. W.; Bemiss, B. C.; Kallwitz, E. R.; Hagen, P. A.; Berg, S.; Frontiers in oncology
  • Exploring health behaviors and the feasibility of a lifestyle intervention for patients with multiple myeloma. Hodge, A.; Sheean, P.; O'Connor, P.; Tyler, K.; Kerschner, A.; Williams, A.; Jensik, K.; Visotcky, A.; D'Souza, A.; Hari, P.; Dhakal, B.; Chhabra, S.; Flynn, K. E.; Hagen, P.; Stolley, M.; Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • Isolated leukemia cutis as extramedullary relapse of acute myeloid leukemia. Dadrass, F.; Esmail, F.; Regmi, A.; Mudaliar, K.; Mirza, K. M.; Kini, A. R.; Kim, W.; Hagen, P.; Hossain, N. M.; Clinical case reports
  • The molecular mechanism and challenge of targeting XPO1 in treatment of relapsed and refractory myeloma. Sellin, M.; Berg, S.; Hagen, P.; Zhang, J.; Translational oncology
  • High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions. Hagen, P.; Zhang, J.; Barton, K.; Blood cancer journal
  • Increasing genomic discovery in newly diagnosed multiple myeloma: defining disease biology and its correlation to risk. Hagen, P.; Sellin, M.; Berg, S.; Zhang, J.; Annals of hematology
  • COVID-19 thromboembolism incidence, risk factors, and anticoagulation practices from a Chicago metropolitan US population. Berg, S.; Kim, S. H.; Wozniak, A.; Odetola, O.; Arain, S.; Aleem, A.; Coggan, J.; Dave, A.; Elliott, E.; Guerrettaz, R.; Dalal, H.; Lee, R.; Kodali, A.; Moore, P.; Patel, S.; Rajakumar, P.; Qin, S.; Delgado Ramos, G.; Schwartz, C.; Esmail, F.; Feltman Frank, R.; Murchie, E.; Pax, L.; Yun, N.; Zhang, Y.; Barton, K.; Hagen, P.; Hossain, N.; Larson, M. L.; Mai, H.; Nand, S.; Phelan, K.; Venugopal, P.; Stiff, P.; Saraf, S.; American journal of hematology
  • Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis. Pasvolsky, O.; Yeshurun, M.; Fraser, R.; Estrada-Merly, N.; Rozovski, U.; Shargian-Alon, L.; Assal, A.; Banerjee, R.; Bumma, N.; Gale, R. P.; Hagen, P.; Holmberg, L.; Hossain, N. M.; Lazarus, H. M.; Lee, C.; Mian, H.; Miller, K. C.; Nathan, S.; Nagler, A.; Nishihori, T.; Parrondo, R. D.; Patel, S.; Schroeder, M. A.; Usmani, S. Z.; Wang, T.; Wirk, B.; Kumar, S.; Shah, N.; Qazilbash, M. H.; D'Souza, A.; Bone marrow transplantation
  • Time to Complete Response after Defibrotide Initiation in Hepatic Veno-Occlusive Disease: Is Less Actually More? Hagen, P.; Hossain, N.; Transplantation and cellular therapy
  • Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimen. Hagen, P.; D'Souza, A.; Hari, P.; Davila, O.; Zhang, M. J.; Vesole, D. H.; Smith, S. E.; Rodriguez, T. E.; Stiff, P. J.; Leukemia & lymphoma
  • When Monoclonal Gammopathy is of Renal Significance: A Case Study of Crystalglobulinemia From Chicago Multiple Myeloma Rounds. Gilmore, B. A.; Rodby, R. A.; Cimbaluk, D.; Venugopal, P.; Patel, P.; Barton, K.; Hagen, P.; Rodriguez, T.; Sumoza, L.; Bishop, M. R.; Dhakal, B.; Hari, P.; Paner, A.; Clinical lymphoma, myeloma & leukemia
  • The Role of Salvage Second Autologous Hematopoietic Cell Transplantation in Relapsed Multiple Myeloma. Hagen, P. A.; Stiff, P.; Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • Low mean post-transplantation tacrolimus levels in weeks 2-3 correlate with acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation from related and unrelated donors. Hagen, P. A.; Adams, W.; Smith, S.; Tsai, S.; Stiff, P.; Bone marrow transplantation